A detailed history of Two Sigma Investments, LP transactions in Inhibrx, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 78,400 shares of INBX stock, worth $1.11 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
78,400
Previous 7,900 892.41%
Holding current value
$1.11 Million
Previous $300,000 813.33%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.76 - $39.56 $2.31 Million - $2.79 Million
70,500 Added 892.41%
78,400 $2.74 Million
Q4 2023

Feb 14, 2024

SELL
$14.5 - $38.0 $2.9 Million - $7.59 Million
-199,770 Reduced 96.2%
7,900 $300,000
Q3 2023

Nov 14, 2023

SELL
$15.75 - $26.31 $830,812 - $1.39 Million
-52,750 Reduced 20.26%
207,670 $3.81 Million
Q2 2023

Aug 14, 2023

SELL
$16.96 - $27.82 $1.28 Million - $2.1 Million
-75,383 Reduced 22.45%
260,420 $6.76 Million
Q1 2023

May 15, 2023

BUY
$18.45 - $27.14 $1.66 Million - $2.44 Million
89,802 Added 36.5%
335,803 $6.34 Million
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $1.67 Million - $2.75 Million
82,512 Added 50.47%
246,001 $6.06 Million
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $454,677 - $970,998
39,264 Added 31.61%
163,489 $2.94 Million
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $566,171 - $1.68 Million
66,452 Added 115.02%
124,225 $1.41 Million
Q1 2022

May 16, 2022

BUY
$19.89 - $43.18 $1.15 Million - $2.49 Million
57,773 New
57,773 $1.29 Million
Q2 2021

Aug 16, 2021

SELL
$14.69 - $27.52 $259,836 - $486,773
-17,688 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$16.27 - $41.26 $287,783 - $729,806
17,688 New
17,688 $355,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.